AbbVie Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $61.2 | $56.3 | $54.3 | $58.1 | $56.2 |
| Operating income | $15.1 | $9.1 | $12.8 | $18.1 | $17.9 |
| Net income | $4.2 | $4.3 | $4.9 | $11.8 | $11.5 |
| Balance Sheet | |||||
| Total debt | $65.0 | $67.1 | $59.4 | $63.3 | $76.7 |
| Cash Flow Statement | |||||
| Free cash flow | $17.8 | $17.8 | $22.1 | $24.2 | $22.0 |
| Dividends | $11.7 | $11.0 | $10.5 | $10.0 | $9.3 |
| Share repurchases | $1.0 | $1.7 | $2.0 | $1.5 | $0.9 |
Shares outstanding 1.8B · Free float 99.9%
Annual filing data through FY ended December 31, 2025; float as of September 11, 2026.
Earnings
Other Coverage
October 10, 2026
Weekly Earnings
Delta and PepsiCo lower earnings outlooks as revenue rises
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
AbbVie’s Rinvoq offers oral treatment for a defined colitis population
September 23, 2026
Drug Pipeline
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
September 23, 2026
Drug Pipeline
AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis
September 4, 2026
Deals
AbbVie Completes $10.9 Billion Cash Purchase of Apogee
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 22, 2026
Deals
AbbVie to Buy Apogee Therapeutics in $10.9 Billion All-Cash Deal